Form 8-K - Current report:
SEC Accession No. 0001193125-24-279715
Filing Date
2024-12-16
Accepted
2024-12-16 17:20:59
Documents
19
Period of Report
2024-12-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d738809d8k.htm   iXBRL 8-K 33497
2 EX-1.1 d738809dex11.htm EX-1.1 197528
3 EX-5.1 d738809dex51.htm EX-5.1 10335
4 EX-99.1 d738809dex991.htm EX-99.1 8490
8 GRAPHIC g738809dsp5.jpg GRAPHIC 2032
9 GRAPHIC g738809dsp6.jpg GRAPHIC 1792
10 GRAPHIC g738809dsp7.jpg GRAPHIC 5612
  Complete submission text file 0001193125-24-279715.txt   452800

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA trvi-20241215.xsd EX-101.SCH 2881
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20241215_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20241215_pre.xml EX-101.PRE 11728
21 EXTRACTED XBRL INSTANCE DOCUMENT d738809d8k_htm.xml XML 3768
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 241552852
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)